https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/
Anyone who sat through the video of that compounding advisory committee meeting — where peptides that 503a/b pharmacies have used for years were being lined up for a de facto ban — will have noticed that almost every speaker, and the room generally, opposed the restrictions. The committee faced a very hostile crowd and went ahead and voted for restrictions on peptides anyway.